Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 14:48:28 GMT 2023
by
admin
on
Sat Dec 16 14:48:28 GMT 2023
|
| Protein Sub Type | |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
B3NS2A8BJ7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
P11597
Created by
admin on Sat Dec 16 14:48:29 GMT 2023 , Edited by admin on Sat Dec 16 14:48:29 GMT 2023
|
PRIMARY | |||
|
B3NS2A8BJ7
Created by
admin on Sat Dec 16 14:48:29 GMT 2023 , Edited by admin on Sat Dec 16 14:48:29 GMT 2023
|
PRIMARY |
| From | To |
|---|---|
| 1_143 | 1_184 |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_88 |
| N | 1_240 |
| N | 1_341 |
| N | 1_396 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
INHIBITOR -> TARGET |
Potential best-in-class CETP inhibitor, which was only discontinued as a backup due to the success of its predecessor, anacetrapib in Ph. III.
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Evacetrapib did not impact aldosterone levels or blood pressure, even while achieving more substantial modulation of HDL and LDL levels than torcetrapib. Unfortunately, it also did not offer clinical benefit in terms of reducing CV events and has been discontinued.
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
SELECTIVE
|
||
|
INHIBITOR -> TARGET |
SELECTIVE
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|